IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Medical and Surgical Science, University of Bologna, Bologna, Italy.
Neurogastroenterol Motil. 2023 Dec;35(12):e14615. doi: 10.1111/nmo.14615. Epub 2023 May 27.
Diverticular disease (DD) is a common condition in Western countries. The role of microbiota in the pathogenesis of DD and its related symptoms has been frequently postulated since most complications of this disease are bacteria-driven and most therapies rely on microbiota modulation. Preliminary data showed fecal microbial imbalance in patients with DD, particularly when symptomatic, with an increase of pro-inflammatory and potentially pathogenetic bacteria. In addition, bacterial metabolic markers can mirror specific pathways of the disease and may be even used for monitoring treatment effects. All treatments currently suggested for DD can affect microbiota structure and metabolome compositions.
Sparse evidence is available linking gut microbiota perturbations, diverticular disease pathophysiology, and symptom development. We aimed to summarize the available knowledge on gut microbiota evaluation in diverticular disease, with a focus on symptomatic uncomplicated DD, and the relative treatment strategies.
憩室病（DD）是西方国家的一种常见病症。由于这种疾病的大多数并发症都是由细菌驱动的，而且大多数治疗方法都依赖于微生物群的调节，因此微生物群在 DD 的发病机制及其相关症状中的作用经常被推测。初步数据显示，DD 患者的粪便微生物失衡，特别是在有症状时，促炎和潜在致病性细菌增加。此外，细菌代谢标志物可以反映疾病的特定途径，甚至可用于监测治疗效果。目前建议用于 DD 的所有治疗方法都可能影响微生物群结构和代谢组组成。
目前关于肠道微生物群紊乱与憩室病发病机制和症状发展之间的关联证据有限。本研究旨在总结憩室病肠道微生物群评估的现有知识，重点关注有症状但无并发症的憩室病，并对相关治疗策略进行概述。
